Nexvet Biopharma PLC (NVET1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Mark Heffernan
Employees:
28
UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN ROAD, TULLAMORE , CO. OFFALY, IRELAND R35 FR98
353 1 215 8100

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Nexvet Biopharma PLC operates as a clinical-stage biopharmaceutical company, whichc engages in the development and commercialization of novel, species-specific biologics based on human biologics for companion animals. Its product candidates include NV-01, a monoclonal antibody (mAb) that targets and inhibits the function of nerve growth factor (NGF) for the control of pain associated with osteoarthritis in dogs; NV-02, a mAb that is an NGF inhibitor for the control of pain associated with degenerative joint disease, including osteoarthritis in cats; and NV-08, a fusion protein that is a tumor necrosis factor inhibitor for the treatment of chronic inflammatory diseases comprising atopic dermatitis in dogs. The company was founded in September 2014 and is headquartered in Dublin, Ireland.

Data derived from most recent annual or quarterly report
Market Cap 80.08 Million Shares Outstanding11.917 Million Avg 30-day Volume 16.582 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.68
Price to Revenue0.0 Debt to Equity0.0112 EBITDA-22.296 Million
Price to Book Value2.2164 Operating Margin0.0 Enterprise Value32.069 Million
Current Ratio5.332 EPS Growth-2.966 Quick Ratio4.085
1 Yr BETA -0.9039 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-52.9484 Altman Z-Score1.5576 Free Cash Flow to Firm -21.007 Million
View SEC Filings from NVET1 instead.

View recent insider trading info

Funds Holding NVET1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NVET1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FARALLON CAPITAL MANAGEMENT LLC

FARALLON PARTNERS L L C/CA

AKUBRA INVESTORS, LLC

BUSHRANGER FUNDING, LLC

UTE HOLDINGS, LLC

FARALLON AA G.P., L.L.C.

FARALLON PARTNERS GP VI, L.L.C.

NGP, L.L.C.

DREYFUSS PHILIP D

FISCH MICHAEL B.

  • 10% Owner
  • MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%
No longer subject to file 2017-07-31 0

FRIED RICHARD B

KIM DAVID T

LANDRY MONICA R

LINN MICHAEL G

PAIDIPATY RAVI K

ROBERTS THOMAS G. JR.

SEYBOLD WILLIAM

SPOKES ANDREW J M

WARREN JOHN R.

WEHRLY MARK C

  • 10% Owner
  • MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%
No longer subject to file 2017-07-31 0

PATEL RAJIV A

  • Director
No longer subject to file 2017-07-31 0

LISMORE DAMIAN T. CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2017-07-31 0

PAYNE JOHN BERNARD

  • Director
No longer subject to file 2017-07-31 0

FARRELL GERALDINE T VP OPERATIONS, GENERAL COUNSEL

  • Officer
No longer subject to file 2017-07-31 0

BROWN CHRISTOPHER NIGEL

  • Director
No longer subject to file 2017-07-31 0

HANNA ASHRAF

  • Director
No longer subject to file 2017-07-31 0

HEFFERNAN MARK CHIEF EXECUTIVE OFFICER

  • Officer
No longer subject to file 2017-07-31 0

KILTY CORMAC G

  • Director
No longer subject to file 2017-07-31 0

MCCRACKEN JOSEPH S

  • Director
No longer subject to file 2017-07-31 0

GUNN GEORGE W

  • Director
No longer subject to file 2017-07-31 0

HORN JURGEN CHIEF PRODUCT DEVELOPMENT OFCR

  • Officer
No longer subject to file 2017-07-31 0

PAIDIPATY RAVI K

  • 10% Owner
  • MEMBER OF GROUP OWNING 10%
2,648,696 2017-01-01 0

SEYBOLD WILLIAM

  • 10% Owner
  • MEMBER OF GROUP OWNING 10%
2,648,696 2017-01-01 0

DREYFUSS PHILIP D

  • 10% Owner
  • MEMBER OF GROUP OWNING 10%
2,648,696 2017-01-01 0

HIRSCH DANIEL J.

  • 10% Owner
  • MEMBER OF GROUP OWNING 10%
No longer subject to file 2016-12-31 0

GEARING DAVID CHIEF SCIENTIFIC OFFICER

  • Officer
431,269 2016-11-07 0

FARALLON CAPITAL MANAGEMENT LLC

FARALLON PARTNERS L L C/CA

FISCH MICHAEL B.

FRIED RICHARD B

HIRSCH DANIEL J.

KIM DAVID T

LANDRY MONICA R

LINN MICHAEL G

ROBERTS THOMAS G. JR.

SPOKES ANDREW J M

  • 10% Owner
  • MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%
6,212,975 2016-02-24 0

GILES COLIN VP CLINICAL&REGULATORY AFFAIRS

  • Officer
0 2015-09-03 0

WALD GRAEME

  • Director
No longer subject to file 2015-07-15 0

ADAGE CAPITAL PARTNERS GP LLC

ADAGE CAPITAL PARTNERS, L.P.

ADAGE CAPITAL ADVISORS, L.L.C.

ATCHINSON ROBERT

GROSS PHILLIP

  • 10% Owner
No longer subject to file 2015-02-10 0

AKUBRA INVESTORS, LLC

BUSHRANGER FUNDING, LLC

FARALLON AA G.P., L.L.C.

FARALLON PARTNERS GP VI, L.L.C.

NGP, L.L.C.

UTE HOLDINGS, LLC

WARREN JOHN R.

WEHRLY MARK C

  • 10% Owner
  • MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%
5,864,170 2015-02-10 0

ONE FUNDS MANAGEMENT LTD ATF ASIA PACIFIC HEALTHCARE FUND II

  • 10% Owner
No longer subject to file 2015-02-10 0

FARALLON CAPITAL MANAGEMENT LLC

FARALLON PARTNERS L L C/CA

FISCH MICHAEL B.

FRIED RICHARD B

HIRSCH DANIEL J.

KIM DAVID T

LANDRY MONICA R

LINN MICHAEL G

PATEL RAJIV A

ROBERTS THOMAS G. JR.

  • 10% Owner
  • MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%
0 2015-02-04 0

AKUBRA INVESTORS, LLC

BUSHRANGER FUNDING, LLC

FARALLON AA G.P., L.L.C.

FARALLON PARTNERS GP VI, L.L.C.

NGP, L.L.C.

SPOKES ANDREW J M

UTE HOLDINGS, LLC

WARREN JOHN R.

WEHRLY MARK C

  • 10% Owner
  • MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%MEMBER OF GROUP OWNING 10%
0 2015-02-04 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments